No Data
No Data
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
On Monday, Revelation Biosciences Inc (NASDAQ:REVB) announced safety and biomarker data for its Phase 1 study (RVL-HV02).The primary endpoint to evaluate the safety and tolerability of escalating dose
Revelation Biosciences Shares Jump on Positive Results for Investigational Drug Gemini
Revelation Biosciences' (REVB) shares surged 33% in recent trading Monday after the company announced its investigational drug Gemini met the primary endpoint of safety and tolerability of escalating
Express News | Revelation Biosciences Inc - Gemini Administration Induced Statistically Significant, Dose Dependent Changes in Key Biomarkers of Activity
Express News | Revelation Biosciences Inc - Gemini Was Safe and Well Tolerated at Pharmacologically Active Doses-
Express News | Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
Revelation Biosciences Completes Enrollment And Dosing In First Human Phase 1 Study Of Gemini; Top-Line Data To Include Safety, Tolerability, And Biomarkers; Supports Future Development Across Multiple Indications
Revelation Biosciences Completes Enrollment And Dosing In First Human Phase 1 Study Of Gemini; Top-Line Data To Include Safety, Tolerability, And Biomarkers; Supports Future Development Across Multipl
No Data
easygoing Lyon : you buy high? or shorting?
103642046OP easygoing Lyon: low
Dreamer88 : Can I go back to 3.5?
韭菜是我是我 Dreamer88: Looks like it doesn't work.